Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 231

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

NCCN Guidelines Insights: Central Nervous System Cancers, Version 1.2017

Open access
Nabors, Louis Burt, Portnow, Jana, Ammirati, Mario, Baehring, Joachim, Brem, Henry, Butowski, Nicholas, Fenstermaker, Robert A., Forsyth, Peter, Hattangadi-Gluth, Jona, Holdhoff, Matthias, Howard, Steven, Junck, Larry, Kaley, Thomas, Kumthekar, Priya, Loeffler, Jay S., Moots, Paul L., Mrugala, Maciej M., Nagpal, Seema, Pandey, Manjari, Parney, Ian, Peters, Katherine, Puduvalli, Vinay K., Ragsdale, John, Rockhill, Jason, Rogers, Lisa, Rusthoven, Chad, Shonka, Nicole, Shrieve, Dennis C., Sills, Allen K., Swinnen, Lode J., Tsien, Christina, Weiss, Stephanie, Wen, Patrick Yung, Willmarth, Nicole, Bergman, Mary Anne, Engh, Anita · 2017 · Journal of the National Comprehensive Cancer Network

Abstract

For many years, the diagnosis and classification of gliomas have been based on histology. Although studies including large populations of patients demonstrated the prognostic value of histologic phenotype, variability in outcomes within histologic groups limited the utility of this system. Nonetheless, histology was the only proven and widely accessible tool available at the time, thus it was used for clinical trial entry criteria, and therefore determined the recommended treatment options. Research to identify molecular changes that underlie glioma progression has led to the discovery of molecular features that have greater diagnostic and prognostic value than histology. Analyses of these molecular markers across populations from randomized clinical trials have shown that some of these markers are also predictive of response to specific types of treatment, which has prompted significant changes to the recommended treatment options for grade III (anaplastic) gliomas.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.6004/jnccn.2017.0166

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 231

Metadata

Authors
Nabors, L. B., Portnow, J., Ammirati, M., Baehring, J., Brem, H., Butowski, N., Fenstermaker, R. A., Forsyth, P., Hattangadi-Gluth, J., Holdhoff, M., Howard, S., Junck, L., Kaley, T., Kumthekar, P., Loeffler, J. S., Moots, P. L., Mrugala, M. M., Nagpal, S., Pandey, M., Parney, I., Peters, K., Puduvalli, V. K., Ragsdale, J., Rockhill, J., Rogers, L., Rusthoven, C., Shonka, N., Shrieve, D. C., Sills, A. K., Swinnen, L. J., Tsien, C., Weiss, S., Wen, P. Y., Willmarth, N., Bergman, M. A., & Engh, A.
Venue
Journal of the National Comprehensive Cancer Network
Published
2017-11
Volume
15
Issue
11
Pages
1331-1345
ISSN
  • 1540-1405 (ISSN-L)
  • 1540-1413
OpenAlex
W2183991412
Cited by
231
References
5
FWCI
12.85
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: NCCN Guidelines Insights: Central Nervous System Cancers, Version 1.2017. https://app.cochat.ai/papers/10.6004/jnccn.2017.0166
The paper
Nabors, L. B., Portnow, J., Ammirati, M., Baehring, J., Brem, H., Butowski, N., Fenstermaker, R. A., Forsyth, P., Hattangadi-Gluth, J., Holdhoff, M., Howard, S., Junck, L., Kaley, T., Kumthekar, P., Loeffler, J. S., Moots, P. L., Mrugala, M. M., Nagpal, S., Pandey, M., . . . Engh, A. (2017). NCCN Guidelines Insights: Central Nervous System Cancers, Version 1.2017. Journal of the National Comprehensive Cancer Network. https://doi.org/10.6004/jnccn.2017.0166

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.